U.S. Hospitality Stock News

Kosmos Energy (KOS) is back in focus after Ghana’s parliament formally ratified license extensions for the Jubilee and TEN offshore fields to 2040, tied to up to US$2b of planned investment. See our latest analysis for Kosmos Energy. The licence news comes after a sharp shift in sentiment around Kosmos, with a 30 day share price return of 58.46% and a 90 day share price return of 88.99% lifting year to date share price gains to 130.73%. This is despite the 1 year total shareholder return...

Earlier this month, FedEx filed a landmark lawsuit in the U.S. Court of International Trade seeking a full refund plus interest on trade duties it paid under President Trump’s emergency tariffs, after the Supreme Court ruled those levies unlawful. This makes FedEx one of the first major U.S. companies to test how far the ruling can go in reversing tariff-era costs, with potential implications for both its own finances and importers across the logistics sector. We’ll now examine how FedEx’s...

XP (NasdaqGS:XP) is back in focus after reporting fourth quarter and full year 2025 results, with higher revenue and net income than a year earlier, alongside continued customer growth and AI driven efficiency gains. See our latest analysis for XP. XP’s recent earnings update and the fresh US$215.6m shelf registration come against a share price of US$21.69, with a 34.05% year to date share price return and a 50.47% total shareholder return over one year, while the five year total shareholder...

Summit Therapeutics (SMMT) has drawn fresh attention after recent share price swings, with the stock up over the past week but showing declines over the month and past 3 months. See our latest analysis for Summit Therapeutics. At the latest share price of $16.09, Summit Therapeutics pairs a solid 1-week share price return of 7.55% with a weaker year-to-date share price return of an 8.16% decline. Its very large 3-year total shareholder return points to a stock where sentiment has shifted...

Earlier in February 2026, Bristol Myers Squibb reported positive Phase 2 results for Reblozyl in adults with alpha-thalassemia and secured FDA acceptance, with Priority Review and Breakthrough Therapy Designation, for its iberdomide New Drug Application in relapsed or refractory multiple myeloma. Together, these advances highlight the growing importance of Reblozyl and the iberdomide CELMoD program within Bristol Myers Squibb’s efforts to counter future patent expiries. We’ll now explore how...

How Dillard's Stock Has Been Moving Dillard's (DDS) has been drawing attention after a recent stretch of mixed share performance, with a 3.6% decline over the past day contrasting with gains over the past month and year. For context, the stock is trading around $646.18, with a return of roughly 2.9% over the past month and 40.7% over the past year. Over the past 3 months, the share price shows a 3.1% decline, while year to date it is up about 1.5%. See our latest analysis for...

AtaiBeckley (NasdaqGM:ATAI) has appointed Michael Faerm as Chief Financial Officer. Faerm will oversee the company’s financial strategy and operations. The company highlighted his prior experience across multiple biopharmaceutical companies. For investors, this move sits at the intersection of leadership and late stage drug development, since AtaiBeckley is advancing several programs through the clinical funnel. In biopharma, the CFO role often covers areas ranging from clinical funding...

Levi Strauss (LEVI) is on investors’ radar after recent share price moves, with the stock closing at $21.76. That price now sits alongside mixed short term returns and stronger multi year performance. See our latest analysis for Levi Strauss. The recent 1 day share price return of a 4.9% decline and a softer 7 day move sit against a 1 year total shareholder return of 18.37% and a 3 year total shareholder return of 34.95%. This suggests that longer term momentum has been stronger than the...

Why Moody's Stock Is On Investors' Radar Today Moody's (MCO) is drawing attention after a period of mixed recent returns, including a 2.4% one day decline and weaker performance over the past month and past 3 months. See our latest analysis for Moody's. The recent 1 month share price return of 16.6% and 1 year to date share price return of 12.4% decline contrast with a 3 year total shareholder return of 54.3% and 5 year total shareholder return of 61.0%. This points to fading short term...

If you are wondering whether Ingredion's current share price really reflects what the business is worth, you are not alone. This article will walk through that question step by step. Ingredion's share price closed at US$116.06, with returns of a 1.9% decline over the last 7 days, a 0.7% decline over 30 days, a 5.7% gain year to date, and an 8.6% decline over 1 year, while the 3 year and 5 year returns sit at 25.0% and 49.3% respectively. Recent coverage around Ingredion has focused on its...

What Hagerty’s recent performance might mean for investors Hagerty (HGTY) has recently seen mixed share performance, with a 1 day return of about a 1.5% decline and a past 3 months decline of roughly 13.5%, while its 1 year total return stands near 14.8%. See our latest analysis for Hagerty. With the share price at US$11.58, Hagerty’s recent 7 day share price return of a 4.0% decline and 30 day share price return of an 8.0% decline point to fading short term momentum, even as the 1 year and 3...

If you are wondering whether Astera Labs' share price lines up with its underlying value, this article walks through what the numbers actually say about the stock. Astera Labs recently closed at US$128.24, with returns of a 0.8% decline over 7 days, a 24.4% decline over 30 days and a 28.6% decline year to date, while the 1-year return stands at 51.5%. Recent news coverage has focused on Astera Labs as a semiconductor player linked to high speed connectivity and data center trends, which...

Phillips 66 (NYSE:PSX) announced that its board has approved an increase in the company’s quarterly dividend. The higher dividend will apply to the next regular quarterly payout to shareholders. Phillips 66 is a diversified energy manufacturing and logistics company, with operations that span refining, midstream, chemicals and marketing. For investors who focus on income, a change in the dividend is often one of the clearest, most concrete data points to watch. A higher regular payout can...

Ivanhoe Electric Inc. recently reported its full-year 2025 results, with sales of US$3.24 million and a net loss of US$105.87 million, improving from the prior year’s deeper loss. The company also reported a fourth-quarter loss of US$34 million, highlighting that while it remains unprofitable, its annual loss and loss per share narrowed compared with 2024. Next, we’ll consider how Ivanhoe Electric’s narrowing net loss and modest revenue increase shape its investment narrative for...

The recent national launch of Tide evo, a concentrated waterless detergent tile, puts Procter & Gamble (PG) back in the spotlight for investors watching how product design and sustainability shape long term demand. See our latest analysis for Procter & Gamble. That focus on new formats like Tide evo and refreshed product lines comes as Procter & Gamble’s share price has picked up momentum, with a 30 day share price return of 10.0% and a year to date share price return of 16.49%, even though...

Texas Capital Bancshares (NasdaqGS:TCBI) has simplified its capital structure by eliminating unused classes of preferred and nonvoting stock. A board director recently made a significant insider purchase of TCBI shares, signaling personal commitment to the company. Both actions highlight changes in capital structure and insider alignment that had not been covered previously. Texas Capital Bancshares, the parent of Texas Capital Bank, focuses on commercial and consumer banking services in...

Alkami Technology's digital banking platform has been selected by State Bank of Texas to modernize its customer experience. The partnership focuses on upgrading online and mobile banking capabilities for the bank's customers. This client win adds to Alkami's presence in the regional and community banking space. For investors watching Alkami Technology (NasdaqGS:ALKT), this new agreement with State Bank of Texas comes at a time when the shares trade at $15.48. The stock has seen a 25.0%...

Recent share performance sets the context Arthur J. Gallagher (AJG) has seen its share price under pressure recently, with a one-month return of around a 15% decline and a past three-month return of about a 14% decline, setting a cautious backdrop for investors. See our latest analysis for Arthur J. Gallagher. At around $214.33 per share, Arthur J. Gallagher’s recent 30 day share price return of about a 15% decline and year to date share price return of roughly a 16% decline contrast with a 5...

Why International Flavors & Fragrances is on investors’ radar International Flavors & Fragrances (IFF) has drawn fresh attention after recent share price moves, with the stock up around 12% over the past month and about 19% in the past 3 months. See our latest analysis for International Flavors & Fragrances. Set against a longer track record that includes a 1 year total shareholder return of 5.72% and a 5 year total shareholder return of 32.43% decline, the recent 30 day share price return of...

McCormick (MKC) has put an automatic mixed securities shelf registration in place, covering common stock, non voting common stock, and debt securities. This is a financing step that could affect future capital structure and trading sentiment. See our latest analysis for McCormick. Against this backdrop, McCormick’s 30 day share price return of 14.38% and 90 day share price return of 3.54% suggest improving momentum, although the 1 year total shareholder return of 12.16% decline points to a...

In February 2026, Harrow, Inc. launched PharmaPack, a direct-to-prescriber cash-pay kit program that offers affordable, fully priced-upfront FDA-approved ophthalmic products as alternatives to off-label compounded formulations for cataract surgery patients, while bypassing insurance hurdles. This move could be important for eye surgeons and patients because it aims to simplify access, reduce regulatory and medical-legal risk, and potentially shift prescribing away from compounded products...

What Cadence Design Systems (CDNS) investors are watching right now Cadence Design Systems (CDNS) has drawn investor attention after a recent pullback, with the share price showing negative returns over the past week, month, and past 3 months, prompting closer scrutiny of the underlying business trends. For context, the stock is down about 5.6% over the past day, 6.6% over the past week, 12.1% over the past month, and 7.9% over the past 3 months, based on the latest available data. At the...

Aramark snapshot after recent share performance Aramark (ARMK) has seen mixed share performance recently, with a 0.9% decline over the past day but gains over the past week, month, and past 3 months putting the stock back in focus for investors. See our latest analysis for Aramark. While the 1 day share price return of 0.9% is soft, Aramark’s recent 7 day and 90 day share price returns of 4.1% and 6.9% sit alongside a 10.4% 1 year total shareholder return and a 57.2% 3 year total shareholder...

Why EQT (EQT) is on investors’ radar EQT (EQT) has drawn investor attention after recent trading left the stock with a 1 day return of 2.4% and a past month return of 6.3%, compared with a 19.3% total return over the past year. See our latest analysis for EQT. At a share price of US$59.03, EQT’s recent swingy pattern, including a 6.3% 30 day share price return alongside a 10.4% year to date share price return, contrasts with a much stronger 5 year total shareholder return of 241.7%. This...